Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators, including the Company’s ...

BOSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary ...

Pulmonary fibrosis is a deadly disease in which the lungs become thickened and scarred, gradually losing their ability to deliver oxygen to the body. Now, scientists at UC San Francisco have ...

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF). This is the first new therapy in more than 10 years to be approved for ...

Tvardi Therapeutics has failed its first big test as a public company. Months after joining the Nasdaq, the biotech has reported the unappetizing mix of high dropout rates and placebolike efficacy in ...

The bold question-askers at What If explore what daily life was like during the Middle Ages. Trump administration looking to sell nearly 200 commissary stores Border Patrol commander Bovino ordered to ...

It's quick and easy to access Live Science Plus, simply enter your email below. We'll send you a confirmation and sign you up for our daily newsletter, keeping you up to date with the latest science ...

More than 10 years after bringing one of the first idiopathic pulmonary fibrosis (IPF) drugs to market, Boehringer Ingelheim is freshening up its leadership in the rare lung disease space with a newly ...

What Is Jascayd, and Why Does It Matter? Jascayd (nerandomilast) is a new oral medicine approved to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF is a rare and serious condition that causes ...

Credit: Boehringer Ingelheim. Nerandomilast reduces the expression of pro-fibrotic growth factors and inflammatory cytokines, commonly overexpressed in IPF. Findings showed nerandomilast led to a ...

Boehringer Ingelheim established a presence in idiopathic pulmonary fibrosis years ago with a drug that has become a standard treatment for this serious lung disorder. Now the company has the ...